文献速递肿瘤 PET/CT甲状腺核医学

FDG-PET/CT代谢参数在转移性放射性碘难治性分化型甲状腺癌中的预后价值

Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
PubMed 文献 · Clin Nucl Med · 2018-01-01

回顾性研究纳入62例转移性放射性碘难治性分化型甲状腺癌患者,中位随访11.1年。基线FDG-PET/CT的MTV和TLG高于中位值与更差的无进展生存相关(P=0.007),对总生存的关联未达统计学显著(P=0.06)。结论认为MTV和TLG可用于该人群的动态风险分层。

要点

  • 诊断转移性放射性碘难治性分化型甲状腺癌后5年总生存概率为34%,中位总生存3.56年。
  • 5年无进展生存概率为19%,中位无进展生存1.31年。
  • MTV和TLG高于中位值与更差的无进展生存相关(P=0.007)。

核心结论

  • FDG-PET/CT代谢参数有助于界定转移性肿瘤负荷的体积和生物学变异。
  • MTV和TLG可用于转移性放射性碘难治性分化型甲状腺癌患者关于无进展生存的动态风险分层,并补充Tg-DT用于临床病程预后。

研究设计与样本

  • 回顾性研究,纳入62例转移性放射性碘难治性分化型甲状腺癌患者,自初诊起中位随访11.1年(8.38,14.1)(范围1.2-20年)。
  • 基线FDG-PET/CT定性评估区域和远处转移,并采用梯度分割法定量获得MTV和TLG评估肿瘤负荷。

主要发现

  • 诊断转移性放射性碘难治性疾病后,5年总生存概率为34%,中位总生存为3.56年(2.87,无穷)。
  • 5年无进展生存概率为19%,中位无进展生存为1.31年(1.03,2.38)。
  • TSH抑制状态下甲状腺球蛋白大于100 ng/mL和甲状腺球蛋白倍增时间小于6个月与更差的总生存和无进展生存显著相关。
  • MTV和TLG高于中位值与更差的总生存(P=0.06)和无进展生存(P=0.007)相关。
  • log-MTV较高者死亡风险更高(HR 1.17,95%CI 0.99-1.39,P=0.05),log-TLG较高者死亡风险更高(HR 1.14,95%CI 1.00-1.31,P=0.05)。

关键数值与推荐

  • TSH抑制状态下甲状腺球蛋白大于100 ng/mL和甲状腺球蛋白倍增时间小于6个月与更差的总生存和无进展生存显著相关。
  • MTV和TLG高于中位值与更差的无进展生存相关(P=0.007),与总生存的关联为P=0.06。

临床怎么用

  • 原文结论认为MTV和TLG可用于转移性放射性碘难治性分化型甲状腺癌患者关于无进展生存的动态风险分层,并补充Tg-DT用于临床病程预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are no standardized prognostication algorithms for metastatic radioiodine-refractory (RAI-R) differentiated thyroid cancer (DTC). We hypothesize that [F]-FDG PET/CT may predict progression versus stability of disease based on quantitative analysis of metabolic tumor volume (MTV) and total lesion glycolysis (TLG). METHODS: Retrospective study of 62 patients with metastatic RAI-R DTC to determine clinical outcomes with median follow-up from initial diagnosis of 11.1 years (8.38, 14.1) (range, 1.2-20 years). Baseline [F]-FDG PET/CT scans were evaluated qualitatively for regional and distant metastases and quantitatively for tumor burden based on MTV and TLG obtained using gradient segmentation method. RESULTS: After diagnosis of metastatic RAI-R disease was established, the 5-year overall survival (OS) probability was 34%, and median OS was 3.56 years (2.87, infinity). The 5-year progression-free survival (PFS) probability was 19%, and median PFS was 1.31 years (1.03, 2.38). TSH-suppressed thyroglobulin (Tg) levels greater than 100 ng/mL and Tg doubling time (Tg-DT) less than 6 months were significantly associated with worse OS and PFS. Higher than median values of MTV and TLG were associated with worse OS (P = 0.06) and PFS (P = 0.007). Higher hazard of death was noted for higher values of log-MTV and log-TLG (HR, 1.17 [95% confidence interval, 0.99-1.39], P = 0.05, and HR, 1.14 [95% confidence interval, 1.00-1.31], P = 0.05, respectively). CONCLUSIONS: [F]-FDG PET/CT metabolic parameters can help define the volume and biologic variations of metastatic tumor burden. Metabolic tumor volume and TLG can be used for dynamic risk stratification of patients with metastatic RAI-R DTC regarding PFS and complement Tg-DT for prognosis of clinical disease course.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Manohar PM, Beesley LJ, Bellile EL, et al. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med. 2018. PMID: 30015659. doi:10.1097/RLU.0000000000002193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。